In vitro Activities of β-Lactam-β-Lactamase Inhibitor Antimicrobial Agents Against Cystic Fibrosis Respiratory Pathogens.

In vitro Activities of β-Lactam-β-Lactamase Inhibitor Antimicrobial Agents Against Cystic Fibrosis Respiratory Pathogens. Antimicrob Agents Chemother. 2019 Oct 14;: Authors: Caverly LJ, Spilker T, Kalikin LM, Stillwell T, Young C, Huang DB, LiPuma JJ Abstract We tested the in vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420 Burkholderia, Achromobacter, Stenotrophomonas, and Pandoraea strains, 89% of which were cultured from respiratory specimens from persons with cystic fibrosis. Among the β-lactam-β-lactamase inhibitor agents, meropenem-vaborbactam had the greatest activity against Burkholderia and Achromobacter; including multi-drug-resistant and extensively-drug-resistant strains. None of the newer β-lactam-β-lactamase combination drugs showed increased activity compared to older agents against Stenotrophomonas maltophilia or Pandoraea spp. PMID: 31611364 [PubMed - as supplied by publisher]
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research